While ACPA-positive has always been a more severe subset of RA, up-to-date treatment strategies have made the disease burden comparable in many aspects for ACPA-positive and ACPA-negative patients with RA [19]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.